- Home
- AGI vs HALO Comparison
AGI vs HALO Comparison
Compare AGI & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGI
- HALO
- Stock Information
- Founded
- AGI 2003
- HALO 1998
- Country
- AGI Canada
- HALO United States
- Employees
- AGI N/A
- HALO N/A
- Industry
- AGI Precious Metals
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AGI Basic Materials
- HALO Health Care
- Exchange
- AGI Nasdaq
- HALO Nasdaq
- Market Cap
- AGI 10.8B
- HALO 7.4B
- IPO Year
- AGI 1999
- HALO N/A
- Fundamental
- Price
- AGI $26.25
- HALO $54.54
- Analyst Decision
- AGI Buy
- HALO Buy
- Analyst Count
- AGI 4
- HALO 9
- Target Price
- AGI $30.38
- HALO $63.56
- AVG Volume (30 Days)
- AGI 4.2M
- HALO 3.3M
- Earning Date
- AGI 04-30-2025
- HALO 05-06-2025
- Dividend Yield
- AGI 0.38%
- HALO N/A
- EPS Growth
- AGI 19.70
- HALO 55.40
- EPS
- AGI 0.62
- HALO 3.76
- Revenue
- AGI $1,402,300,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- AGI $30.00
- HALO $25.77
- Revenue Next Year
- AGI $10.74
- HALO $18.01
- P/E Ratio
- AGI $42.64
- HALO $14.51
- Revenue Growth
- AGI 33.63
- HALO 25.64
- 52 Week Low
- AGI $15.01
- HALO $42.01
- 52 Week High
- AGI $31.00
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- AGI 50.87
- HALO 44.48
- Support Level
- AGI $25.55
- HALO $52.43
- Resistance Level
- AGI $26.29
- HALO $54.26
- Average True Range (ATR)
- AGI 0.69
- HALO 3.42
- MACD
- AGI 0.03
- HALO -0.49
- Stochastic Oscillator
- AGI 70.62
- HALO 30.60
About AGI Alamos Gold Inc.
Alamos Gold Inc acquires, explores, and produces gold and other precious metals, and operates in two principal geographic areas: Canada and Mexico. The company has four operating segments being Young-Davidson, Island Gold and Magino mines operate in Canada, and the Mulatos mine operates in Sonora, Mexico. The company generates maximum revenue from the Mulatos mines.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.